A New Era in the Treatment of Chronic Kidney Disease

We are a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate that aims to transform the therapeutic landscape in advanced Chronic Kidney Disease (CKD) with the potential to preserve kidney function in patients who face limited options for care apart from preparing for dialysis.

Our Mission

ProKidney is a pioneer in the treatment of CKD. While current treatments can slow the progression of CKD to End Stage Kidney Disease (ESKD), there is no cure for CKD. ProKidney is at the forefront in the field of cellular therapy focused on preserving kidney function and potentially delaying or eliminating the need for dialysis.

Addressing an Area of High Unmet Need

Over 35 million U.S adults have CKD with approximately 135,000 patients progressing to dialysis every year. Therapeutic options to delay the need for dialysis in patients with Stage 4 CKD are limited. While approved therapies for patients with CKD have been shown to delay disease progression in some patients, many continue to lose kidney function and progress to ESKD. Management of patients in Stage 4 CKD is largely focused on addressing their comorbidities and preparing them for dialysis.

rilparencel (previously known as REACT®)

Early clinical data suggest that ProKidney’s cell therapy candidate, rilparencel, has the potential to preserve kidney function and potentially delay or eliminate the need for dialysis.

Lead Platform Programs for CKD Treatment

ProKidney and REACT aim to disrupt the CKD treatment landscape